Molecular biomarkers predicting early development of endometrial carcinoma: A pilot study.
biomarkers
cancer gene mutations
endometrial cancer
Journal
European journal of cancer care
ISSN: 1365-2354
Titre abrégé: Eur J Cancer Care (Engl)
Pays: England
ID NLM: 9301979
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
06
11
2018
revised:
08
05
2019
accepted:
22
06
2019
pubmed:
15
8
2019
medline:
23
4
2020
entrez:
15
8
2019
Statut:
ppublish
Résumé
Endometrial carcinoma represents the most common gynaecological cancer and the sixth most frequent cancer among women worldwide. The 5-year survival of patients with stage I endometrial carcinoma is 75%-88% versus 50% for stage III or 15% for stage IV disease. Therefore, early detection could improve survival rates. Specifically, in the most prevalent, type 1 endometrial cancer develops from hyperplastic endometrium. The aim of the study was to evaluate the utility of cancer gene mutations from endometrial biopsies towards predicting synchronous or metachronous development of malignant lesions. The aim of the study was to evaluate whether endometrial biopsies could already carry mutations in cancer genes useful for predicting or anticipating subsequent cancer development. Patients with a previous endometrial biopsy negative for cancer, followed by a subsequent biopsy positive for cancer, were included in the study. A fifty cancer genes targeted next-generation sequencing panel were used to investigate mutations in matched non-cancerous and malignant samples. All biopsies from cancer tissues harboured mutations in one or more of the following genes: APC, CTNNB1, FBXW7, HNF1A, KRAS, MTOR, NRAS, PIK3CA, PTEN, RB1 and TP53. Additionally, 50% of the biopsies from matched non-cancerous tissues exhibited mutations in PTEN, KRAS or PIK3CA genes. These results suggest that detecting pathogenic mutations in oncogenes or tumour suppressor genes in an otherwise benign condition is associated with a risk of developing a malignant disease. Given the identification of mutations several months or years before the appearance of a malignancy, our finding suggests that a closer monitoring of patients who present such molecular alterations in non-cancerous uterine mass is warranted.
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Pagination
e13137Subventions
Organisme : Grants from University of Ferrara
ID : University of Ferra
Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Antonsen, S. L., Ulrich, L., & Hogdall, C. (2012). Patients with atypical hyperplasia of the endometrium should be treated in oncological centers. Gynecologic Oncology, 125, 124-128.
Bakkum-Gamez, J. N., Wentzensen, N., Maurer, M. J., Hawthorne, K. M., Voss, J. S., Kroneman, T. N., … Sherman, M. E. (2015). Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. Gynecologic Oncology, 137, 14-22.
Bokhman, J. V. (1983). Two pathogenetic types of endometrial carcinoma. Gynecologic Oncology, 15, 10-17.
Chang, Y. S., Huang, H. D., Yeh, K. T., & Chang, J. G. (2016). Genetic alterations in endometrial cancer by targeted next-generation sequencing. Experimental and Molecular Pathology, 100, 8-12.
Cancer Genome Atlas Research Network, Kandoth, C., Schultz, N., Cherniack, A. D., Akbani, R., Liu, Y., … Levine, D. A. (2013). Integrated genomic characterization of endometrial carcinoma. Nature, 497, 67-73.
Lortet-Tieulent, J., Ferlay, J., Bray, F., & Jemal, A. (2017). International patterns and trends in endometrial cancer incidence, 1978-2013. Journal of the National Cancer Institute, 110(4), 354-361. https://doi.org/10.1093/jnci/djx214
Lupini, L., Bassi, C., Mlcochova, J., Musa, G., Russo, M., Vychytilova-Faltejskova, P., … Negrini, M. (2015). Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients. BMC Cancer, 15, 808.
Noer, M. C., Antonsen, S. L., Ottesen, B., Christensen, I. J., & Hogdall, C. (2018). Type I versus Type II endometrial cancer: Differential impact of comorbidity. International Journal of Gynecological Cancer, 28, 586-593.
Pearson-Stuttard, J., Zhou, B., Kontis, V., Bentham, J., Gunter, M. J., & Ezzati, M. (2018). Worldwide burden of cancer attributable to diabetes and high body-mass index: A comparative risk assessment. Lancet Diabetes Endocrinol, 6, 95-104.
Querleu, D., Cibula, D., & Abu-Rustum, N. R. (2017). 2017 update on the querleu-morrow classification of radical hysterectomy. Annals of Surgical Oncology, 24, 3406-3412.
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014). Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Research, 74, 2913-2921. https://doi.org/10.1158/0008-5472.CAN-14-0155
Reed, S. D., Newton, K. M., Clinton, W. L., Epplein, M., Garcia, R., Allison, K., … Weiss, N. S. (2009). Incidence of endometrial hyperplasia. American Journal of Obstetrics and Gynecology, 200(678), e1-6.
Slomovitz, B. M., & Coleman, R. L. (2012). The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clinical Cancer Research, 18, 5856-5864.
Society, A. C (2018). Facts & figures 2018 [Online]. Available. [Accessed] https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf
Suhaimi, S. S., Ab Mutalib, N. S., & Jamal, R. (2016). Understanding Molecular Landscape of Endometrial Cancer through Next Generation Sequencing: What We Have Learned so Far? Front Pharmacol, 7, 409. https://doi.org/10.3389/fphar.2016.00409